Daclatasvir/pegIFN Lambda/RBV or Telaprevir/pegIFN Alfa/RBV in HCV G1b

• Research type

  Research Study

• Full title

  AI452-021 - A Phase 3 Evaluation of Daclatasvir in Combination with Peginterferon Lambda-1a and Ribavirin (RBV) or Telaprevir in Combination with Peginterferon Alfa-2a and RBV in Patients with Chronic Hapatitis C Genotype 1b who are Treatment Naive or Prior Relapsers to Alfa/RBV Therapy

• IRAS ID

  118002

• Contact name

  Kosh Agarwal

• Contact email

  kosh.agarwal@nhs.net

• Sponsor organisation

  Bristol Myers Squibb

• Eudract number

  2011-005409-65

• ISRCTN Number

  No number provided

• Clinicaltrials.gov Identifier

  No number provided

• REC name

  London - Brent Research Ethics Committee

• REC reference

  13/LO/0206

• Date of REC Opinion

  18 Apr 2013

• REC opinion

  Further Information Favourable Opinion